Hub Group Reaches New 52-Week High (HUBG)

NEW YORK ( TheStreet) -- Hub Group (Nasdaq: HUBG) hit a new 52-week high Wednesday as it is currently trading at $40.74, above its previous 52-week high of $39.29 with 97,202 shares traded as of 10:06 a.m. ET. Average volume has been 215,600 shares over the past 30 days.

Hub Group has a market cap of $1.4 billion and is part of the services sector and transportation industry. Shares are up 6.8% year to date as of the close of trading on Tuesday.

Hub Group, Inc., an asset-light freight transportation management company, provides intermodal, truck brokerage, and logistics services in North America. Its intermodal services consist of arranging for the movement of customers' freight in containers and trailers over long distances. The company has a P/E ratio of 32.5, equal to the average transportation industry P/E ratio and above the S&P 500 P/E ratio of 16.3.
  • Practice your HUBG trading strategies and win cash in our stock game.

TheStreet Ratings rates Hub Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full Hub Group Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus